Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Don W Stone who wrote (250)	1/30/1998 8:17:00 AM
From: Rick Strange	Read Replies (2) \| Respond to of 507

Don, You are reading conclussions into Dr Schellekens statements that are not supported by fact. You say:"Dr Schellekens says the multipomponent vaccines may cause a smaller or later epidemic." He never said that and it is a leap of fantasy to draw such a conclussion. NVX's monocomponent is pertussis toxoid (PT). Every accellular pertussis vaccine on the American market or waiting for approval also has pertussis toxoid (PT) so explian the competative advantage that you see in this situation enjoyed by NVX?